CD38 and esophageal cancer: A recent study showed that a CD38 mAb released T‐cell suppression by CD38‐expressing myeloid‐derived suppressor cells (MDSCs) resulting in a decreased tumor growth rate in an in vivo model of esophageal cancer 39.